Good Manufacturing Practice and Schedule M
On this page
Direct answer
Schedule M of the Drugs and Cosmetics Rules, 1945 is India's legal text of Good Manufacturing Practice — the premises, plant, equipment, personnel and quality-system requirements a manufacturer must satisfy for a manufacturing licence to mean anything. It mandates segregated, purpose-built areas for each operation, an independent quality control unit with its own laboratory, defined storage including quarantined and rejected zones, trained staff under separate heads of production and quality control, and full documentation — batch records, SOPs, validation and self-inspection. The revised Schedule M notified at the end of December 2023 (G.S.R. 761(E)) modernised this baseline toward WHO-GMP norms, importing a pharmaceutical quality system, quality risk management, ISO 14644-style clean-area classification for sterile plants and data-integrity expectations, with staggered deadlines giving smaller units time to comply — the most examinable regulatory development of the decade.
What you must remember
- Legal position: Schedule M is prescribed under the Drugs and Cosmetics Act, 1940 framework; non-compliance is direct ground for licence action, and its requirements are what drug inspectors audit against.
- The 2023 revision pillars: pharmaceutical quality system, quality risk management, qualification and validation, vendor audits, complaint and recall systems, data integrity (ALCOA principles), and ISO 14644-aligned clean-area grades for sterile manufacture.
- Layout logic: unidirectional flow of men and materials through airlocks; separate areas for penicillins and beta-lactams, steroids, hormones and cytotoxics because of sensitisation and cross-contamination risk.
- Personnel: separate qualified heads of production and quality control, trained technical staff, gowning and hygiene SOPs, health checks.
- Water and utilities: validated purified water and water-for-injection systems; HVAC with preventive maintenance and calibration.
- Documentation spine: master formula, batch manufacturing and packing records, SOPs with change control, deviation and out-of-specification investigation, product quality review, sample retention.
- Timelines: the revision applied quickly to larger companies, while units with annual turnover up to about Rs 250 crore were given extended compliance time (commonly cited toward end-2025).
- Sterile-specific: Grade A to D classified areas, media-fill validation of aseptic lines, filter integrity testing and environmental monitoring programmes.
Reading the schedule as an inspection unfolds
Walk a formulation plant the way a drug inspector does. Entry: change rooms and airlocks — is material flow unidirectional, or do dispatched cartons cross the dispensing corridor? Dispensing: a separate area with dust extraction, issued material weighed against the batch record. Tablet suites are pressure-cascaded against the corridor; a penicillin or steroid block must be a separate building or isolated zone with dedicated air handling, Schedule M's oldest enforcement teeth. The quality control laboratory sits outside production's chain of command, releasing or rejecting batches in writing; the revised Schedule M elevates that independence into a full quality system with management review and self-inspection. In the stores, quarantine, approved and rejected zones are physically labelled, rejected goods awaiting documented destruction. The inspector's final hour is spent on paper — batch records reconciling yield, deviation logs, validation protocols, training files — because GMP's thesis is that a product is only as good as the documented evidence behind it.
Where candidates stumble
The recurring confusion is Schedule M versus Schedule Y — one letter, different universes; Schedule M is manufacturing GMP, while clinical-trial requirements lived under Schedule Y until the New Drugs and Clinical Trials Rules, 2019 superseded it, and mixing them wastes the whole question. The second slip is treating GMP as a building checklist: examiners now expect the revision's system vocabulary — risk management, data integrity, product quality review — because the 2023 amendment moved Indian law from bricks to systems. Third, quote the turnover-linked timelines approximately and honestly (about Rs 250 crore; extension toward end-2025 for smaller units), since over-precise wrong dates cost more than hedged right ones. Finally, remember ASU units answer to Schedule T, not Schedule M — the favourite cross-reference trap across the legislation paper.
Frequently asked questions
What does Schedule M of the Drugs and Cosmetics Rules prescribe?
The good manufacturing practice requirements — premises, plant, equipment, personnel, quality control, documentation and quality systems — a pharmaceutical manufacturer must meet for licence validity.
What changed in the revised Schedule M notified in December 2023?
It added a pharmaceutical quality system, quality risk management, data integrity norms, vendor qualification, ISO 14644-aligned clean-area classification for sterile plants and stricter validation, with phased deadlines for smaller manufacturers.
Why do penicillin and steroid manufacture demand separate areas?
Their extreme sensitisation and cross-contamination potential at trace levels requires isolated, dedicated facilities with independent air handling so other products cannot carry residues to sensitive patients.
Who must head production and quality control under Schedule M?
Separately qualified, designated heads — production and quality control must be independent functions, so the unit testing and releasing batches is never subordinate to the unit making them.
How does Schedule M differ from Schedule T?
Schedule M governs allopathic pharmaceutical manufacture, while Schedule T lays down the separate GMP requirements for Ayurvedic, Siddha and Unani medicines.